New drug for advanced bladder, colorectal, stomach, or pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new investigational drug called MGC030 for people with advanced solid tumors, including bladder, colorectal, stomach, esophageal, or pancreatic cancer. The goal is to see if the drug is safe and can help shrink or control the cancer when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancers: bladder/urinary tract, colorectal, stomach/esophageal, or pancreatic cancer.
- Your cancer must have spread or cannot be removed by surgery, and standard treatments have stopped working or you cannot tolerate them.
- You must have at least one tumor that can be measured by a scan.
- You must have a tumor sample available from a past biopsy or be willing to get a new one.
- You must be in generally good health, with acceptable blood test results, and use effective birth control if you can become pregnant.
- You cannot have active brain metastases, a history of organ or stem cell transplant, or another cancer treated in the last 2 years (except very low-risk skin cancer, low-grade prostate cancer, or carcinoma in situ).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MGC026 that targets a protein called B7-H3 on cancer cells, aiming to shrink or slow different advanced solid tumors. It is an early-phase study to find the right dose and check safety.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests two new drugs (BL-B01D1 and SI-B003) alone or with a standard immunotherapy for advanced gastrointestinal cancers. The goal is to see if these combinations shrink tumors and are safe.
This trial studies a new immunotherapy drug (SHR-1701) combined with standard chemoradiotherapy for people with advanced stomach or esophagus cancer that cannot be surgically removed. The goal is to see if adding this immune treatment helps control the tumor better than standard treatments alone.
This study tests a new drug called MGC028 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
Hear when a new Urothelial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.